7,949 Results

Positive Phase III INNOVATE trial for Imbruvica + rituximab for Waldenström's macroglobulinemia.- AbbVie.

 Added 1 day ago

AbbVie announced the Phase III iNNOVATE (PCYC-1127) trial evaluating Imbruvica (ibrutinib) in combination with rituximab in patients with treatment-naïve and...

At ASH meeting Seattle Genetics updates results of ALCANZA trial of Adcetrisfor cutaneous anaplastic large cell lymphoma.

 Added 1 day ago

Seattle Genetics, Inc. highlighted updated results from the phase III ALCANZA clinical trial evaluating Adcetris (brentuximab vedotin) in CD30-expressing cutaneous...

Cyramza achieves progression free survival but not overall survival in Phase III RAINBOW trial for gastric cancer.- Eli Lilly.

 Added 1 day ago

Eli Lilly and Company announced top-line results from its Phase III RAINFALL study of Cyramza (ramucirumab) in combination with cisplatin...

Phase III results show Abraxane leads to high disease-free survival rates in breast cancer.- Celgene.

 Added 2 days ago

The German Breast Group and Celgene announced long-term invasive disease-free survival results from the GeparSepto clinical trial comparing the investigational...

NICE recommends Maviret to treat all genotypes Hepatitis C.-AbbVie

 Added 2 days ago

The National Institute for Health and Care Excellence (NICE) has recommended Maviret (glecaprevir + pibrentasvir) from AbbVie for adults with...

NICE recommends Zykadia to treat adults with untreated ALK positive NSCLC.-Novartis.

 Added 2 days ago

The National Institute for Health and Care Excellence (NICE) in draft guidance has recommended Zykadia (ceritinib) from Novartis as an...

Successful Phase III study of Kalydeco for children aged 1 to 2 years with cystic fibrosis CFTR gene.- Vertex

 Added 2 days ago

Vertex Pharmaceuticals Incorporated announced positive results from an open-label Phase III study of Kalydeco (ivacaftor) in children with cystic fibrosis...

Call to update guidelines on fertility in Breast Cancer following successful trial

 Added 3 days ago

Data presented at the San Antonio Breast Cancer Symposium has suggested that a temporary ovarian suppression with hormone analog may preserve fertility during breast cancer chemotherapy

Phase III trial data support current standard 12-month adjuvant Trastuzumab for HER2-positive breast cancer

 Added 3 days ago

Nine weeks of trastuzumab may be sufficient for patients who receive higher dose of docetaxel.

Breast cancer patients undergo years of unnecessary treatment

 Added 3 days ago

Just two years of extended Anastrozole therapy shown to be equally effective as five years.

Load more